ArticlePloS one2022

Targeting caveolae to pump bispecific antibody to TGF-β into diseased lungs enables ultra-low dose therapeutic efficacy.

Anil H Kadam et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.